retatrutide clinical trials latest Trial of next-gen weight-loss drug brings it one step closer to FDA approval AllWell - Everyone keeps asking
Description
The theory is compelling
This medication works by mimicking a hormone called GLP-1 (glucagon-like peptide-1), which targets areas of the brain that regulate appetite and food intake
New neurological symptoms : Numbness, weakness, loss of sensation, or difficulty walking may indicate peripheral neuropathy or other neurological conditions requiring investigation
Unlike semaglutide, tirzepatide influences another hormone, GIP, alongside GLP-1, to assist insulin release and appetite suppression
But daily behavior protects that momentum
Neumiller, PharmD, CDCES, FADCES, FASCP, can be reached at [email protected]
